New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
08:31 EDTNKTRNektar announces initiation of Phase 2 study of etirinotecan pegol
Nektar announced the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The primary endpoint of the Phase 2 study is overall response rate. Secondary endpoints include progression free survival, overall survival, median duration of response and the safety profile of etirinotecan pegol in patients with NSCLC after failure of second-line therapy. The open label, single-arm trial is expected to enroll approximately 37 patients who will receive etirinotecan pegol once every three weeks as monotherapy.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
07:31 EDTNKTRNektar announces MOVENTIG receives positive CHMP opinion in EU
Subscribe for More Information
September 24, 2014
10:35 EDTNKTRHigh option volume stocks
Subscribe for More Information
September 19, 2014
09:01 EDTNKTRNektar presents preclinical data on kappa opioid receptor
Nektar announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system, and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models. However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects.
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use